Rheumatoid Arthritis vs Osteoarthritis: How to Tell Them Apart
Rheumatoid arthritis (RA) and osteoarthritis (OA) share a word and a symptom, joint pain, and not much else. OA is a degenerative disease of the whole joint, very common with age, injury and excess weight, and it mostly hurts with use. RA is an autoimmune disease in which the immune system attacks the joint lining, often in the small joints of both hands and feet, and it can affect the whole body. The two need very different treatment, and with RA the timing matters: the first months are a window when treatment works best. This page sets the two side by side, explains which signs point toward inflammatory arthritis, and shows where gout and psoriatic arthritis fit. Every major claim carries an evidence grade.
Key takeaways
- OA is a whole-joint degenerative disease with low-grade local inflammation. RA is a systemic autoimmune disease with marked synovial inflammation. Strong
- OA is far more common: about 595 million people worldwide had it in 2020, compared with about 17.6 million with RA.45 Strong
- The most useful bedside clue is morning stiffness: under 30 minutes suggests OA, while more than 30 minutes (often over an hour) suggests inflammatory arthritis. Strong
- Anti-CCP is about 95% specific for RA, but about a third of people with RA test negative. There is no blood test for OA.10 Strong
- Early RA treatment is linked to about one-third less long-term X-ray progression, so persistent joint swelling deserves prompt medical assessment.11 Strong
- You can have both: OA is common with age, and long-standing RA damage can lead to secondary OA. Strong
RA vs OA at a glance: the comparison table Strong
This table summarizes the typical picture of each disease, drawn from major reviews and guidelines.123 Real people do not always read the textbook, so treat it as a guide to the questions a clinician will ask, not as a self-diagnosis tool. Each row is explained in more detail below.
| Feature | Rheumatoid arthritis (RA) | Osteoarthritis (OA) |
|---|---|---|
| What it is | Chronic autoimmune disease; the immune system attacks the synovium (joint lining) | Degenerative disease of the whole joint: cartilage loss, bone remodeling, osteophytes, low-grade synovitis |
| Main drivers | Genetic susceptibility (HLA-DRB1 "shared epitope") plus environmental triggers, especially smoking | Age, joint injury, obesity and metabolic health, joint shape and alignment, genetics |
| Typical age at onset | Any adult age; most often between the 30s and 60s | Usually after 40–50 and rising steeply with age; earlier after joint injury |
| Sex | About 2.5 times more common in women5 | About 60% of people with OA are women |
| Speed of onset | Weeks to months; sometimes abrupt | Gradual, over months to years |
| Joints typically affected | Small joints: knuckles (MCPs), middle finger joints (PIPs), wrists, balls of the feet (MTPs); larger joints later. Usually spares the finger-end joints (DIPs) | Weight-bearing and heavily used joints: knees, hips, spine, base of the thumb, finger-end (DIP) and middle (PIP) joints. Usually spares wrists and knuckles |
| Symmetry | Usually symmetrical (same joints on both sides) | Often asymmetrical, or one joint worse than its partner |
| Swelling feels | Soft, warm, "boggy" (synovitis and fluid) | Hard, bony (osteophytes, Heberden's and Bouchard's nodes); sometimes a cool effusion |
| Morning stiffness | More than 30 minutes, often over an hour | Under 30 minutes; brief stiffness after sitting ("gelling") |
| Pain pattern | Worst after rest, eases with gentle movement | Worse with use and at the end of the day, eases with rest (early on) |
| Whole-body symptoms | Fatigue, low-grade fever, weight loss; can involve lungs, eyes, skin (nodules), blood vessels; raises cardiovascular risk | None from OA itself; effects are local to the joint (pain, poor sleep, reduced activity) |
| Blood tests | RF and/or anti-CCP positive in about two-thirds; CRP/ESR often raised in active disease | Normal: no diagnostic blood test. Tests are used to rule out other causes |
| Joint fluid | Inflammatory (high white-cell count) | Non-inflammatory (low white-cell count) |
| X-ray findings | Soft-tissue swelling, bone thinning near the joint, erosions at the joint margins, even joint-space narrowing | Uneven joint-space narrowing, osteophytes (bone spurs), subchondral sclerosis and cysts |
| Treatment approach | Disease-modifying drugs (DMARDs) started early, typically methotrexate, with treat-to-target escalation; plus exercise and not smoking | Exercise and weight management first; topical or oral NSAIDs, injections and aids as needed; joint replacement for end-stage hip or knee |
| Prognosis | Untreated: erosions, deformity, disability, higher cardiovascular risk. With early treat-to-target care, remission or low disease activity is realistic for many | Usually slowly progressive and variable; many people stay stable for years. A leading cause of pain and disability in older adults |
For each condition on its own, see the full guides to osteoarthritis and rheumatoid arthritis.
What causes each: autoimmunity vs joint failure Strong
Rheumatoid arthritis
In RA the immune system loses tolerance to some of the body's own proteins. Immune cells invade the synovium, which thickens into an inflamed tissue called pannus that erodes cartilage and bone. Genes (especially HLA-DRB1 "shared epitope" alleles) set the risk, and exposures such as smoking help trigger it. Autoantibodies often appear years before the first swollen joint.2 Read more in what RA is and RA risk factors.
Osteoarthritis
OA used to be called "wear and tear," but it is now understood as failure of the whole joint: cartilage, subchondral bone, synovium, ligaments and fat pad. Load and injury matter, and so do obesity, metabolic health, age and genetics.1 OA does involve inflammation, but it is low-grade and local rather than systemic. See the root drivers of OA and low-grade synovitis.
Mechanism: two kinds of inflammation
Both diseases involve cytokines such as IL-1β, TNF-α and IL-6, which is why some writers blur the line. The difference is scale and origin. In RA, an adaptive immune response (T cells, B cells, autoantibodies) drives intense synovitis that spills into the bloodstream, raising CRP and ESR and affecting other organs. In OA, fragments of damaged cartilage trigger innate-immune signals inside the joint, which keeps a slow breakdown-and-repair cycle going without a strong systemic signal.12 This is one reason drugs that block TNF or IL-6 transform RA but have not shown clear benefit in OA trials.
Which joints, and how: the pattern matters Strong
Clinicians lean heavily on the distribution of affected joints. The hand is the clearest example, because both diseases often show up there but in different places.
| Joint | RA | OA |
|---|---|---|
| Finger-end joints (DIP) | Usually spared | Common (Heberden's nodes) |
| Middle finger joints (PIP) | Common, soft swelling | Common, bony swelling (Bouchard's nodes) |
| Knuckles (MCP) | Very common | Uncommon |
| Base of the thumb (CMC) | Less typical | Very common |
| Wrists | Very common | Uncommon (except after injury) |
| Balls of the feet (MTP) | Very common, often early | Mainly the big toe joint |
| Knees and hips | Can be involved, often later | The most commonly affected joints |
| Spine | Upper neck (C1–C2) in long-standing disease; lower spine rarely | Common in neck and lower back |
RA tends to involve many joints symmetrically, and the 2010 ACR/EULAR classification criteria give the most points for involvement of more than ten joints, including at least one small joint.9 OA more often affects a handful of joints, and knee OA is by far the most common site worldwide.4 An important trap: erosive hand OA can cause painful, swollen, even inflamed-looking finger joints, and it can be mistaken for RA. Its preference for the DIP and PIP joints and normal blood tests usually tell it apart.1
Morning stiffness and how pain behaves Strong
If you remember one question from this page, make it this: how long are your joints stiff when you get up?
Points toward OA
- Stiffness on waking lasting 30 minutes or less
- Brief stiffness after sitting that loosens within minutes
- Pain that builds with activity and eases with rest
- Grating or crunching (crepitus), bony enlargement
Points toward inflammatory arthritis
- Stiffness lasting more than 30 minutes, often an hour or more
- Stiffness and pain worst after rest, better with movement
- Soft, warm swelling in several joints
- Fatigue or feeling unwell alongside joint symptoms
The UK NICE guideline lets clinicians diagnose OA without imaging in people aged 45 or over with activity-related joint pain and either no morning stiffness or stiffness lasting 30 minutes or less.8 EULAR's recommendations for knee OA list persistent pain, limited morning stiffness and reduced function as the key symptoms, with crepitus, restricted movement and bony enlargement as the key signs; when all six were present, the estimated probability of radiographic knee OA reached 99%.7 Longer stiffness does not prove RA, but it should prompt a check for inflammatory arthritis. More on OA symptoms is in the osteoarthritis symptoms section, and RA symptoms in RA symptoms.
Blood tests: RF, anti-CCP, CRP and ESR Strong
No blood test diagnoses OA. In suspected inflammatory arthritis, four tests do most of the work. A 2007 meta-analysis pooled 37 studies of anti-CCP and 50 of rheumatoid factor (RF):10
| Test | In RA | In OA | Caveats |
|---|---|---|---|
| Anti-CCP (ACPA) | Positive in about 67%; specificity about 95% | Negative | Highly specific; a negative result does not rule out RA |
| Rheumatoid factor (IgM RF) | Positive in about 69%; specificity about 85% | Usually negative | Can be positive in other autoimmune diseases, chronic infections and some healthy older adults, so an older person with OA may have a "false alarm" RF |
| CRP | Often raised in active disease | Normal or only slightly raised | Not specific: infection, obesity and many other conditions raise it; can be normal in early RA |
| ESR | Often raised in active disease | Usually normal for age | Rises with age, anemia and pregnancy; slower to change than CRP |
In the 2010 ACR/EULAR criteria, serology (RF and anti-CCP) contributes up to 3 points and an abnormal CRP or ESR 1 point toward the threshold of 6 out of 10.9 People who are negative for both antibodies can still have RA ("seronegative RA"), and in a Leiden cohort, lower CRP and gradual onset were among the features linked to longer delays before people saw a rheumatologist.12 Normal blood tests are not a reason to ignore persistently swollen joints. For how these markers are interpreted, see anti-CCP and RF and CRP and ESR on our biomarkers page, and anti-CCP and rheumatoid factor on the RA page.
Imaging: what X-rays, ultrasound and MRI show Strong
- OA on X-ray: joint-space narrowing that is often uneven (for example worse on the inner side of the knee), osteophytes, subchondral sclerosis and cysts. OA is mostly a clinical diagnosis, and imaging is overused; X-rays help when the picture is atypical or surgery is being considered.18
- RA on X-ray: soft-tissue swelling, thinning of bone next to the joint, even joint-space narrowing and, over time, marginal erosions. Early RA X-rays are often normal, which is why a normal X-ray does not exclude it.2
- Ultrasound and MRI can show synovitis and early erosions before they appear on X-ray, and rheumatologists may use them when examination is uncertain.214 They also show synovitis in many people with OA, so the overall pattern still matters.1
Imaging and joint findings do not always match symptoms. In OA, some people with marked X-ray changes have little pain, and the reverse.1 See the OA diagnosis and RA diagnosis sections for more detail.
Checklist: signs of inflammatory arthritis Strong
- Swelling in one or more joints that is soft or puffy rather than bony and lasts more than a few weeks;
- Morning stiffness lasting more than 30 minutes, especially an hour or more;
- Pain or swelling in the small joints of the hands, wrists or feet, on both sides;
- Pain when someone gently squeezes across your knuckles or the balls of your feet;
- Stiffness that is worse after rest and eases as you move;
- Fatigue, low-grade fever or unexplained weight loss together with joint symptoms;
- A whole finger or toe swollen like a sausage, back pain that improves with exercise, or joint pain with psoriasis, inflammatory bowel disease or a painful red eye;
- A family history of RA, psoriatic arthritis or other autoimmune disease plus new joint symptoms;
- A positive RF or anti-CCP, or raised CRP/ESR, on a previous blood test.
These signs echo the UK NICE RA guideline, which advises referring adults with suspected persistent synovitis for a specialist opinion, and urgently if small joints of the hands or feet are affected, more than one joint is affected, or symptoms have already lasted three months or more, even if blood tests are normal.15 Ask your doctor directly whether a rheumatology referral is needed. Tracking stiffness duration and swollen joints in the flare tracker can make that conversation easier.
Why the distinction matters: the RA window Strong
Mistaking OA for RA leads to unnecessary worry and tests. Mistaking early RA for "just wear and tear" can cost permanent joint damage. The evidence for acting quickly in RA is some of the most consistent in rheumatology:
- A meta-analysis of 12 studies found that starting DMARDs early was associated with a 33% lower rate of long-term radiographic progression than delayed treatment, with benefit lasting up to 5 years, and people with more aggressive disease seemed to benefit most.11
- In 598 people with RA from the Leiden Early Arthritis Clinic, being assessed by a rheumatologist 12 weeks or more after symptoms began was associated with a 1.3-times higher rate of joint destruction over 6 years and a hazard ratio of 1.87 for not achieving drug-free remission. Only 31% were seen within 12 weeks.12
- A JAMA review concluded that early diagnosis and treatment can avert or substantially slow joint damage in up to 90% of patients, with a target of remission or low disease activity within 6 months.3
Honest caveat: experts still debate exactly how long the window is. A 2019 review found strong support for the "classic" idea that treatment in the first two years after diagnosis best prevents damage and disability, while the newer idea that RA can be prevented by treating before arthritis appears is not yet supported by trial evidence.13 EULAR's early arthritis recommendations advise that people with arthritis be referred to, and ideally seen by, a rheumatologist within six weeks of symptom onset.14 Read more in the window of opportunity on our RA page.
Treatment approaches compared Strong
| Element | RA | OA |
|---|---|---|
| Goal | Switch off the immune attack: remission or low disease activity, preventing erosions | Reduce pain, keep function and mobility, slow progression where possible |
| Core first step | Start a DMARD as soon as RA is diagnosed; methotrexate is the usual anchor, often with short-term glucocorticoids1718 | Education, exercise and weight loss if overweight, strongly recommended for everyone16 |
| Strategy | Treat to target: regular disease-activity checks; add a biologic or targeted drug if the target is not reached in about 3–6 months18 | Step up as needed: topical NSAIDs (knee, hand), oral NSAIDs at the lowest effective dose, joint injections, braces and aids16 |
| Advanced options | Biologics (TNF, IL-6, B-cell or T-cell targeted) and JAK inhibitors | Joint replacement for end-stage hip or knee OA that has not responded to other care |
| Exercise | Recommended: improves function, fatigue and cardiovascular health without worsening disease19 | First-line treatment: reduces pain and improves function1619 |
| Who leads care | Rheumatologist, with primary care | Primary care and physical therapy; orthopedics if surgery is considered |
Exercise is the one treatment the two share: EULAR's physical activity recommendations apply to both inflammatory arthritis and hip and knee OA.19 How to adapt it during a flare is covered in exercising during a flare vs. remission. For OA treatment detail, see evidence-graded OA interventions; for RA, see early treatment and complementary measures. In RA, current EULAR guidance notes that stopping DMARDs often leads to a flare even after sustained remission, so any tapering should be planned with your rheumatologist.18
Where lifestyle and root-cause thinking fit Strong (shared levers) Emerging (upstream triggers)
The holistic view and mainstream rheumatology agree more than they disagree here. Several upstream factors matter for both diseases, though in different ways:
- Body weight and metabolic health. High BMI accounts for about a fifth of the global OA burden,4 and obesity is linked to higher RA disease activity and lower remission rates. See obesity and adipokines. Strong
- Smoking. The best-established environmental risk factor for RA, especially anti-CCP-positive RA. Quitting is the most valuable single change for anyone at risk. Strong
- Movement and muscle strength. Protect joints in both conditions. Strong
- Mucosal and gut triggers in RA (gums, lungs, gut microbiome) and "metabolic OA" are plausible, actively studied ideas, but they have not yet produced treatments that replace standard care. See the mucosal origins hypothesis and metabolic OA and inflammaging. Emerging
- Anti-inflammatory eating. A Mediterranean-style pattern is a reasonable, low-risk choice for both, mainly through weight and cardiovascular benefits; disease-specific trial evidence is limited. See the anti-inflammatory diet. Emerging
The broader picture of these shared drivers is on root causes of arthritis.
Where gout and psoriatic arthritis fit Strong
RA and OA are not the only possibilities. Two other common types often enter the conversation:
| Condition | Cause | Typical pattern | Key test |
|---|---|---|---|
| Gout | Urate crystals from long-standing high uric acid | Sudden, intensely painful, red, hot joint, often the big toe, ankle or knee; attacks settle in days to weeks | Urate crystals in joint fluid; serum urate (can be normal during a flare)20 |
| Psoriatic arthritis | Immune-mediated, linked to psoriasis | Can be asymmetrical; finger-end joints, "sausage" fingers or toes, tendon insertions (heels), spine; nail changes | Clinical picture plus psoriasis; RF and anti-CCP usually negative22 |
| Rheumatoid arthritis | Autoimmune synovitis | Symmetrical small joints, prolonged morning stiffness | RF, anti-CCP, CRP/ESR |
| Osteoarthritis | Whole-joint degeneration | Knees, hips, hands, spine; pain with use | Clinical; X-ray if needed |
Gout affected about 3.9% of U.S. adults (9.2 million people) in 2015–2016,21 and it is managed very differently from RA or OA, with urate-lowering therapy to a target. See the full gout guide, including when a hot joint is an emergency. Psoriatic arthritis develops in roughly one in five people with psoriasis (pooled estimate 19.7%),23 and finger-end joint involvement means it can be confused with hand OA. Like RA, it is an inflammatory arthritis that benefits from early rheumatology care.
Can you have both RA and OA? Strong
Yes, and it is common. OA becomes very common with age, so many people with RA develop OA in some joints too. Years of synovitis and erosions in RA can also damage cartilage enough to cause secondary osteoarthritis in the affected joints, which is one reason joint replacement is still sometimes needed after RA is under control.12
This matters in practice. A person with well-controlled RA who develops knee pain that worsens with walking may have OA in that knee rather than an RA flare, and the right response (exercise therapy and weight management rather than escalating immune-suppressing drugs) is different. The reverse also happens: an older adult with known hand OA may develop new symmetrical wrist and knuckle swelling that is actually late-onset RA. Tell your doctor if your symptoms change pattern, and keep taking prescribed treatment while it is assessed.
How common are RA and OA? Strong
The Global Burden of Disease 2021 study estimated that 595 million people had OA in 2020, equal to 7.6% of the world's population and 132% more cases than in 1990, with the knee the most common site.4 The companion RA analysis estimated 17.6 million people with RA in 2020, an age-standardized prevalence of about 209 per 100,000, with women affected about 2.45 times as often as men; it projected 31.7 million cases by 2050.5 In many high-income populations, RA affects roughly 5 in every 1,000 adults.3 In the United States, an estimated 21.2% of adults (53.2 million) reported doctor-diagnosed arthritis in 2019–2021, and 88% of them were aged 45 or older.6
| Condition | Estimate | Source |
|---|---|---|
| Osteoarthritis | 595 million worldwide (2020); 7.6% of the global population | GBD 20214 |
| Rheumatoid arthritis | 17.6 million worldwide (2020); female-to-male ratio about 2.45 | GBD 20215 |
| Gout | 3.9% of U.S. adults (2015–2016) | NHANES21 |
| Psoriatic arthritis | About 19.7% of people with psoriasis | Meta-analysis23 |
| Any diagnosed arthritis | 21.2% of U.S. adults (53.2 million), 2019–2021 | CDC, NHIS6 |
Figures differ between sources because studies define disease differently (for example, symptoms plus X-ray changes for OA versus self-reported diagnosis), so compare estimates from the same source where possible.
When to see a doctor Strong
- a suddenly hot, red, swollen, very painful joint, especially with fever or feeling unwell (possible septic arthritis or gout), and especially if you take immune-suppressing medicines;
- inability to bear weight after an injury, or a visibly deformed joint;
- new neck pain with numbness, tingling or weakness in the arms or legs, or joint pain with loss of bladder or bowel control;
- chest pain or sudden shortness of breath.
Book a prompt appointment (and ask about rheumatology referral) if you have:
- any of the inflammatory arthritis signs above, especially joint swelling lasting more than a few weeks or morning stiffness over 30 minutes;
- a change in your usual pattern of joint pain, such as new swelling in different joints;
- joint pain with rash, psoriasis, eye inflammation, bowel symptoms or unexplained weight loss.
Book a routine appointment if you have:
- joint pain or stiffness lasting more than a few weeks that limits work, sleep or activity;
- OA pain that is worsening despite exercise and weight management, or side effects from pain relievers.
If you already take medicines for RA, OA or another condition, keep taking them as prescribed and discuss any concerns with your doctor or pharmacist. The OA and RA red-flag sections have condition-specific lists.
Frequently asked questions
What is the main difference between rheumatoid arthritis and osteoarthritis?
Rheumatoid arthritis (RA) is an autoimmune disease: the immune system attacks the joint lining, usually in the small joints of both hands and feet, and it can affect the whole body. Osteoarthritis (OA) is a degenerative disease of the whole joint in which cartilage breaks down and bone remodels, most often in the knees, hips, hands and spine, with only low-grade local inflammation. RA needs disease-modifying drugs; OA is managed mainly with exercise, weight management and pain relief. This is educational information, not medical advice.
How can I tell if my joint pain is RA or OA?
Clues that point toward RA include morning stiffness lasting more than 30 minutes (often an hour or more), soft swelling of several joints on both sides of the body, small joints of the hands, wrists and feet, stiffness that eases with movement, and fatigue. OA pain usually worsens with use and eases with rest, morning stiffness lasts under 30 minutes, and swelling is mostly bony. Only a clinician can make the diagnosis, so see a doctor if joints stay swollen for more than a few weeks.
Can a blood test tell RA from OA?
Blood tests help but do not decide it alone. Anti-CCP antibodies are about 95% specific for RA, and rheumatoid factor about 85%, but roughly a third of people with RA test negative for each. Inflammatory markers such as CRP and ESR are often raised in active RA and usually normal in OA. There is no blood test for OA; tests are used to rule other conditions out.
Can you have both rheumatoid arthritis and osteoarthritis?
Yes. OA becomes very common with age, so many people with RA also develop OA, and years of joint inflammation and damage from RA can lead to secondary osteoarthritis in the affected joints. Having both changes how symptoms and treatment are judged, so a rheumatologist should review which condition is driving pain in each joint.
Is rheumatoid arthritis worse than osteoarthritis?
They are serious in different ways. Untreated RA can erode joints within months and raises cardiovascular risk, but early treat-to-target therapy now lets many people reach remission or low disease activity. OA is far more common, about 595 million people worldwide in 2020 versus about 17.6 million with RA, and it is a leading cause of disability in older adults, though it usually progresses slowly.
Why does it matter to tell RA and OA apart early?
Because RA has a window of opportunity. Studies show that starting disease-modifying treatment early is linked to about a one-third lower rate of long-term X-ray progression, and people seen by a rheumatologist within 12 weeks of symptom onset had less joint destruction and more drug-free remission than those seen later. Mistaking early RA for wear and tear can cost permanent joint damage.
References
- Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759. PubMed 31034380
- Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. PubMed 27156434
- Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–1372. PubMed 30285183
- GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508–e522. PubMed 37675071
- GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594–e610. PubMed 37795020
- Fallon EA, Boring MA, Foster AL, et al. Prevalence of diagnosed arthritis — United States, 2019–2021. MMWR Morb Mortal Wkly Rep. 2023;72(41):1101–1107. PubMed 37824422
- Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69(3):483–489. PubMed 19762361
- Osteoarthritis in over 16s: diagnosis and management (NG226). National Institute for Health and Care Excellence (NICE), 2022. nice.org.uk/guidance/ng226
- Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. PubMed 20872595
- Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808. PubMed 17548411
- Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55(6):864–872. PubMed 17139662
- van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537–3546. PubMed 20722031
- Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis — definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870. PubMed 31168406
- Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948–959. PubMed 27979873
- Rheumatoid arthritis in adults: management (NG100). National Institute for Health and Care Excellence (NICE), 2018. nice.org.uk/guidance/ng100
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162. PubMed 31908149
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–939. PubMed 34101387
- Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026;85(6):991–1009. PubMed 41826212
- Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(9):1251–1260. PubMed 29997112
- Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843–1855. PubMed 33798500
- Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. PubMed 30618180
- Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. PubMed 28273019
- Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. PubMed 29928910